Analysts expect STERIS (NYSE:STE) to announce earnings of $1.22 per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for STERIS’s earnings. The lowest EPS estimate is $1.22 and the highest is $1.23. STERIS posted earnings of $1.11 per share in the same quarter last year, which would suggest a positive year over year growth rate of 9.9%. The firm is expected to report its next earnings report on Tuesday, May 8th.
On average, analysts expect that STERIS will report full-year earnings of $4.13 per share for the current financial year, with EPS estimates ranging from $4.13 to $4.14. For the next financial year, analysts expect that the firm will post earnings of $4.71 per share, with EPS estimates ranging from $4.68 to $4.77. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow STERIS.
STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, February 7th. The medical equipment provider reported $1.12 EPS for the quarter, beating the Zacks’ consensus estimate of $1.07 by $0.05. The business had revenue of $661.90 million during the quarter, compared to the consensus estimate of $663.17 million. STERIS had a return on equity of 11.57% and a net margin of 9.42%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.98 earnings per share.
A number of equities research analysts have issued reports on the company. Zacks Investment Research downgraded STERIS from a “buy” rating to a “hold” rating and set a $106.00 price target for the company. in a research report on Thursday. KeyCorp reissued a “buy” rating and set a $103.00 price target on shares of STERIS in a research report on Thursday, February 8th. Northcoast Research set a $102.00 price target on STERIS and gave the company a “buy” rating in a research report on Thursday, February 8th. Finally, Raymond James Financial reissued a “market perform” rating and set a $100.00 price target on shares of STERIS in a research report on Wednesday, January 3rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $85.40.
Shares of NYSE:STE traded up $0.02 during midday trading on Friday, reaching $94.41. The company’s stock had a trading volume of 209,243 shares, compared to its average volume of 344,704. STERIS has a 1 year low of $69.27 and a 1 year high of $96.43. The company has a quick ratio of 2.22, a current ratio of 2.82 and a debt-to-equity ratio of 0.46. The company has a market cap of $8,008.81, a P/E ratio of 25.11 and a beta of 1.12.
The company also recently declared a quarterly dividend, which was paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th were given a dividend of $0.31 per share. This represents a $1.24 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date of this dividend was Tuesday, February 27th. This is an increase from STERIS’s previous quarterly dividend of $0.21. STERIS’s payout ratio is 32.98%.
In other STERIS news, Director Richard Martin Steeves sold 58,953 shares of the business’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $91.00, for a total transaction of $5,364,723.00. Following the transaction, the director now owns 9,362 shares in the company, valued at $851,942. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the business’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $95.50, for a total value of $955,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 78,415 shares of company stock valued at $7,178,536. 2.55% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of STE. Captrust Financial Advisors acquired a new position in shares of STERIS during the fourth quarter worth about $101,000. Meeder Asset Management Inc. lifted its stake in shares of STERIS by 1,122.4% during the fourth quarter. Meeder Asset Management Inc. now owns 1,198 shares of the medical equipment provider’s stock worth $104,000 after purchasing an additional 1,100 shares in the last quarter. YorkBridge Wealth Partners LLC acquired a new position in shares of STERIS during the fourth quarter worth about $113,000. Driehaus Capital Management LLC acquired a new position in shares of STERIS during the fourth quarter worth about $241,000. Finally, QS Investors LLC lifted its stake in shares of STERIS by 36,250.0% during the fourth quarter. QS Investors LLC now owns 2,908 shares of the medical equipment provider’s stock worth $254,000 after purchasing an additional 2,900 shares in the last quarter. Institutional investors own 89.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://ledgergazette.com/2018/04/14/1-22-eps-expected-for-steris-ste-this-quarter.html.
STERIS Company Profile
STERIS plc develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The company's Healthcare Products segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, as well as liquid chemical sterilant processing systems; automated washer/disinfector systems; general and specialty surgical tables, surgical and examination lights, equipment management systems, operating room storage cabinets, warming cabinets, scrub sinks, and other accessories; and gastrointestinal devices and accessories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.